# Microbiotic Product to Promote Microbiome Health and Improve Chemotherapy Delivery

Source: https://onco.cc/trials/nct05296681/  
OnCo record `nct05296681` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in colorectal cancer, run by Howard S. Hochster, MD, now recruiting.

## Summary

Microbiotic Product to Promote Microbiome Health and Improve Chemotherapy Delivery is a phase 2, randomised interventional study registered as NCT05296681 by Howard S. Hochster, MD, with a registry enrolment figure of 42 participants, started 2022-05-03 and due to reach its primary completion in 2026-12. Interventions recorded: NBT-NM108. Conditions listed: Metastatic Colon Carcinoma; Stage IV Colon Cancer AJCC v8; Stage IVA Colon Cancer AJCC v8; Stage IVB Colon Cancer AJCC v8; Stage IVC Colon Cancer AJCC v8. Primary outcome: The number of participants with treatment-related Adverse Events as Assessed by Cancer Therapy Evaluation Program Common Toxicity Criteria (CTCAE) Version 5.0 for toxicity and Adverse Event reporting; Tumor Response by RECIST v1.1 Criteria. Colorectal eligibility wording from the registry: "* Biopsy proven and metastatic colon cancer". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT05296681
- Phase: 2
- Setting: A Randomized Trial of Microbiotic Product (NBT-NM108) to Promote Microbiome Health and Improve Chemotherapy Delivery
- Sponsor: Howard S. Hochster, MD
- Enrolled: 42

## Sources

- ClinicalTrials.gov NCT05296681: https://clinicaltrials.gov/study/NCT05296681

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05296681.json